Taken together, our findings indicated a crucial role of RanBP3 in CML biology, and targeting RanBP3 alone or combined with TKIs could improve the clinical response of CML patients. The gene discussed is RANBP3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.